Sfmg LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sfmg LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.6% in the fourth quarter, HoldingsChannel reports. The firm owned 31,192 shares of the biopharmaceutical company’s stock after selling 1,488 shares during the period. Sfmg LLC’s holdings in Bristol-Myers Squibb were worth $1,600,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. OFI Invest Asset Management purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $25,000. True Wealth Design LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $26,000. Milestone Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $27,000. Coppell Advisory Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $28,000. Finally, Blue Bell Private Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Down 0.5 %

Shares of Bristol-Myers Squibb stock traded down $0.25 during trading on Wednesday, reaching $48.26. The company had a trading volume of 11,931,277 shares, compared to its average volume of 10,940,481. The company has a market cap of $97.81 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39. The firm’s fifty day moving average is $51.27 and its 200-day moving average is $51.62. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a fifty-two week low of $47.58 and a fifty-two week high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.82 EPS. On average, analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Analysts Set New Price Targets

BMY has been the subject of several research reports. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Wells Fargo & Company reduced their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 6th. Finally, Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.